Continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030 By Roots Analysis

Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

 

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Key Market Insights

• Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
• Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
• The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
• Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
• Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
• Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
• Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
• Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
• Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
• As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Table of Contents

 

TABLE OF CONTENTS

 

1.         PREFACE        

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Historical Evolution of Continuous Manufacturing

3.3.       Continuous Manufacturing in the Pharmaceutical Industry

3.3.1.    Regulatory Landscape

3.3.2.    Early Adopters of Continuous Manufacturing

3.3.3.    Anticipated Shift to Continuous Manufacturing

3.3.4.    Advantages of Continuous Manufacturing

3.3.5.    Key Challenges Associated with Continuous Manufacturing

3.3.6.    Future Perspectives

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Purpose of Manufacturing

4.2.4.    Analysis by Scale of Operation

4.2.5.    Analysis by Location of Headquarters

4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

4.2.9.    Analysis by Type of Dosage Form

4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

4.2.11.  Information on Production Capacity

4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

 

5.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

5.1.       Chapter Overview

5.2.       AbbVie Contract Manufacturing

5.2.1.    Company Overview

5.2.2.    Service Portfolio

5.2.3.    Continuous Manufacturing Capabilities and Facilities

5.2.4.    Recent Developments and Future Outlook

 

5.3.       Cambrex

5.3.1.    Company Overview

5.3.2.    Service Portfolio

5.3.3.    Continuous Manufacturing Capabilities and Facilities

5.3.4.    Recent Developments and Future Outlook

 

5.4.       Patheon

5.4.1.    Company Overview

5.4.2.    Service Portfolio

5.4.3.    Continuous Manufacturing Capabilities and Facilities

5.4.4.    Recent Developments and Future Outlook

 

5.5.       SK biotek

5.5.1.    Company Overview

5.5.2.    Service Portfolio

5.5.3.    Continuous Manufacturing Capabilities and Facilities

5.5.4.    Recent Developments and Future Outlook

 

6.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

6.1.       Chapter Overview

6.2.       Ajinomoto Bio-Pharma Services

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Continuous Manufacturing Capabilities and Facilities

6.2.4.    Recent Developments and Future Outlook

 

6.3.       Almac

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Continuous Manufacturing Capabilities and Facilities

6.3.4.    Recent Developments and Future Outlook

 

6.4.       Boehringer Ingelheim BioXcellence™

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Continuous Manufacturing Capabilities and Facilities

6.4.4.    Recent Developments and Future Outlook

 

6.5.       CordonPharma

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Continuous Manufacturing Capabilities and Facilities

6.5.4.    Recent Developments and Future Outlook

 

6.6.       Hovione

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Continuous Manufacturing Capabilities and Facilities

6.6.4.    Recent Developments and Future Outlook

 

6.7.       Lonza

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Continuous Manufacturing Capabilities and Facilities

6.7.4.    Recent Developments and Future Outlook

 

7.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

7.1.       Chapter Overview

7.2.       Kaneka

7.2.1.    Company Overview

7.2.2.    Service Portfolio

7.2.3.    Continuous Manufacturing Capabilities and Facilities

7.2.4.    Recent Developments and Future Outlook     

 

7.3.       WuXi AppTec

7.3.1.    Company Overview

7.3.2.    Service Portfolio

7.3.3.    Continuous Manufacturing Capabilities and Facilities

7.3.4.    Recent Developmen